BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30963193)

  • 21. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
    Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
    Front Immunol; 2021; 12():680973. PubMed ID: 34122444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.
    Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI
    Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
    Ren Y; Lv Q; Yue W; Liu B; Zou Z
    Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
    Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
    Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
    Walsh NM; Fleming KE; Hanly JG; Dakin Hache K; Doucette S; Ferrara G; Cerroni L
    Hum Pathol; 2016 Jun; 52():190-6. PubMed ID: 26980039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
    Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
    Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
    Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
    Hamm CA; Pry K; Lu J; Bacus S
    Exp Mol Pathol; 2019 Aug; 109():1-15. PubMed ID: 30953647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
    Zhang B; Yang L; Wang X; Fu D
    Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
    Kim SW; Kim YI; Mustafa B; Kim MJ; Jeong G; Ahn SM; Lim SB; Yu CS; Kim JC; Hong SM; Park IJ
    Mod Pathol; 2021 Jan; 34(1):141-160. PubMed ID: 32709987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.
    Frydenlund N; Leone D; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Singh R; Biswas A; Yaar R; Mahalingam M
    Mod Pathol; 2017 Mar; 30(3):357-369. PubMed ID: 28084337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
    Kuklinski LF; Yan S; Li Z; Fisher JL; Cheng C; Noelle RJ; Angeles CV; Turk MJ; Ernstoff MS
    Cancer Immunol Immunother; 2018 Jul; 67(7):1113-1121. PubMed ID: 29737375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.